Search

Displaying results 661 - 670 of 1910 in total
  1. Drug

    Sevabertinib

    go.drugbank.com/drugs/DB21667
    ApprovedInvestigational

    Sevabertinib is a kinase inhibitor indicated for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations. Sevaber...

  2. Drug

    Rituximab

    go.drugbank.com/drugs/DB00073
    ApprovedInvestigational

    Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine ...

    Products: MABTHERA® SOLUCIÓN INYECTABLE 1400 MG/11.7 ML (120MG/ML), RITOXEN 10MG/ML
  3. Drug

    Lysine

    go.drugbank.com/drugs/DB00123
    ApprovedInvestigationalNutraceutical

    Lysine (abbreviated as Lys or K) is an α-amino acid with the chemical formula HO2CCH(NH2)(CH2)4NH2. This amino acid is an essential amino acid, which means that humans cannot synthesize it. Its codons are AAA and AAG. Lysine is a base, a...

    Mixtures: KABIVEN 1026 ML, KABIVEN 1540 MLSynonyms: L-lys, L-Lysin
  4. Drug

    VP025

    go.drugbank.com/drugs/DB05133
    Experimental

    VP025, a novel drug formulation based on phospholipid microparticles incorporating phosphatidylglycerol, can inhibit neuroinflammation. VP025 may inhibit immune system activation and protect motoneurons from injury. It also shows the abi...

  5. Drug

    Elosulfase alfa

    go.drugbank.com/drugs/DB09051
    ApprovedInvestigational

    Elosulfase alfa is a synthetic version of the enzyme N-acetylgalactosamine-6-sulfatase. It was approved by the FDA in 2014 for the treatment of Morquio syndrome. Elosulfase alfa was developed by BioMarin Pharmaceutical Inc. and is market...

    Products: Vimizim 1mg/ml Concentrate for Solution for Infusion, VIMIZIM® 1MG/ML SOLUCIÓN CONCENTRADA PARA INFUSIÓN
  6. Drug

    Pholcodine

    go.drugbank.com/drugs/DB09209
    ApprovedIllicit

    Pholcodine formula is 3-o-morpholinoethylmorphine and it is classified as an antitussive which is defined as an opioid cough suppressant. It belongs to the opioid family of compounds and it is widely used. Pholcodine activity is the supp...

    Products: DHACODINE SYRUP 15 mg/5 ml, DURO-TUSS FORTE COUGH LIQUID 45 mg/15 ml
  7. Drug

    Ritobegron

    go.drugbank.com/drugs/DB12080
    Investigational

    Ritobegron is under investigation in clinical trial NCT02256735 (Study to Investigate the Effect of KUC 7483 CL on the QT/QTc Interval of the ECG in Comparison to Placebo and Moxifloxacin in Healthy Male

  8. Drug

    Bexicaserin

    go.drugbank.com/drugs/DB18885
    Investigational

    Bexicaserin is under investigation in clinical trial NCT05626634 (Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy).

  9. Drug

    Fosigotifator

    go.drugbank.com/drugs/DB19409
    Investigational

    Fosigotifator is under investigation in clinical trial NCT05757141 (An Open-label Exploratory Study of ABBV-CLS-7262 Subjects With Vanishing White Matter Disease).

    Synonyms: Sodium ({(2S)-1,4-bis[2-(4-chloro-3- fluorophenoxy)acetamido]bicyclo[2.2.2]octan-2- yl}oxy)methyl hydrogen phosphate - 2-amino-2- (hydroxymethyl)propane-1,3-diol (1/1/1)
  10. Drug

    alpha-Linolenic acid

    go.drugbank.com/drugs/DB00132
    ApprovedInvestigationalNutraceuticalWithdrawn

    Alpha-linolenic acid (ALA) is a polyunsaturated omega-3 fatty acid. It is a component of many common vegetable oils and is important to human nutrition.